(UFPT) UFP Technologies - Overview

Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 1.772m USD | Total Return: -3.2% in 12m

Medical Disposables, Sterile Packaging, Protective Gear, Industrial Components
Total Rating 49
Safety 76
Buy Signal -0.29
Medical Devices
Industry Rotation: +5.3
Market Cap: 1.77B
Avg Turnover: 46.3M
Risk 3d forecast
Volatility45.3%
VaR 5th Pctl7.91%
VaR vs Median5.92%
Reward TTM
Sharpe Ratio0.07
Rel. Str. IBD39.5
Rel. Str. Peer Group58.7
Character TTM
Beta1.390
Beta Downside1.352
Hurst Exponent0.427
Drawdowns 3y
Max DD48.31%
CAGR/Max DD0.29
CAGR/Mean DD0.59
EPS (Earnings per Share) EPS (Earnings per Share) of UFPT over the last years for every Quarter: "2021-03": 0.55, "2021-06": 0.62, "2021-09": 0.52, "2021-12": 0.42, "2022-03": 0.64, "2022-06": 1.17, "2022-09": 2.56, "2022-12": 1.1, "2023-03": 1.27, "2023-06": 1.55, "2023-09": 1.52, "2023-12": 1.51, "2024-03": 1.64, "2024-06": 1.75, "2024-09": 2.1051, "2024-12": 2.46, "2025-03": 2.2099, "2025-06": 2.21, "2025-09": 2.39, "2025-12": 2.44, "2026-03": 2.48,
EPS CAGR: 23.42%
EPS Trend: 94.1%
Last SUE: 0.06
Qual. Beats: 0
Revenue Revenue of UFPT over the last years for every Quarter: 2021-03: 48.599, 2021-06: 50.655, 2021-09: 50.723, 2021-12: 56.343, 2022-03: 71.242, 2022-06: 94.343, 2022-09: 96.97, 2022-12: 91.237, 2023-03: 97.753, 2023-06: 100.037, 2023-09: 100.784, 2023-12: 101.497, 2024-03: 105.009, 2024-06: 110.177, 2024-09: 145.165, 2024-12: 144.07, 2025-03: 148.148, 2025-06: 151.176, 2025-09: 154.558, 2025-12: 148.915, 2026-03: 154.202,
Rev. CAGR: 22.47%
Rev. Trend: 97.2%
Last SUE: -0.13
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: UFPT UFP Technologies

UFP Technologies, Inc. (UFPT) is a designer and manufacturer of high-performance custom components and specialized packaging, primarily serving the medical, aerospace, defense, and automotive sectors. The company utilizes a diverse range of specialized foams, films, and plastics to create mission-critical products such as robotic surgery drapes, biopharma drug manufacturing components, and tactical military gear.

Operating within the Health Care Supplies sub-industry, UFPT focuses on the med-tech sector, where high switching costs and rigorous regulatory requirements often lead to long-term, stable contract manufacturing relationships. The company employs a direct sales model to provide engineered solutions that address specific thermal insulation, acoustic, and filtration needs for industrial and consumer applications.

For a deeper look into the companys valuation metrics and historical performance, consider reviewing the data available on ValueRay.

Founded in 1963 and headquartered in Massachusetts, UFPT maintains a diversified revenue stream by leveraging its engineering expertise across both highly regulated medical markets and cyclical industrial sectors.

Headlines to Watch Out For
  • Medical device acquisition strategy accelerates inorganic revenue growth and market share
  • Robotic surgery adoption increases high-margin sterile packaging and drape demand
  • Shift toward medical-centric portfolio improves overall gross margin profile
  • Supply chain disruptions impact raw material costs for engineered foam components
  • Aerospace and defense contract wins diversify revenue beyond healthcare sectors
Piotroski VR-10 (Strict) 8.0
Net Income: 68.6m TTM > 0 and > 6% of Revenue
FCF/TA: 0.10 > 0.02 and ΔFCF/TA 1.11 > 1.0
NWC/Revenue: 24.16% < 20% (prev 23.01%; Δ 1.15% < -1%)
CFO/TA 0.12 > 3% & CFO 81.3m > Net Income 68.6m
Net Debt (154.5m) to EBITDA (116.3m): 1.33 < 3
Current Ratio: 2.91 > 1.5 & < 3
Outstanding Shares: last quarter (7.80m) vs 12m ago 0.30% < -2%
Gross Margin: 28.35% > 18% (prev 0.29%; Δ 2.81k% > 0.5%)
Asset Turnover: 92.44% > 50% (prev 85.20%; Δ 7.23% > 0%)
Interest Coverage Ratio: 10.60 > 6 (EBITDA TTM 116.3m / Interest Expense TTM 8.73m)
Altman Z'' 6.03
A: 0.22 (Total Current Assets 224.1m - Total Current Liabilities 77.0m) / Total Assets 674.7m
B: 0.58 (Retained Earnings 392.3m / Total Assets 674.7m)
C: 0.14 (EBIT TTM 92.6m / Avg Total Assets 658.7m)
D: 1.67 (Book Value of Equity 394.4m / Total Liabilities 235.8m)
Altman-Z'' = 6.03 = AAA
Beneish M -3.01
DSRI: 0.95 (Receivables 102.6m/96.9m, Revenue 608.9m/547.6m)
GMI: 1.02 (GM 28.35% / 28.99%)
AQI: 0.96 (AQ_t 0.52 / AQ_t-1 0.54)
SGI: 1.11 (Revenue 608.9m / 547.6m)
TATA: -0.02 (NI 68.6m - CFO 81.3m) / TA 674.7m)
Beneish M = -3.01 (Cap -4..+1) = AA
What is the price of UFPT shares?

As of May 27, 2026, the stock is trading at USD 229.06 with a total of 212,031 shares traded.
Over the past week, the price has changed by +5.45%, over one month by +16.10%, over three months by +6.21% and over the past year by -3.20%.

Is UFPT a buy, sell or hold?

UFP Technologies has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold UFPT.

  • StrongBuy: 1
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the UFPT price?
Analysts Target Price 324.5 41.7%
UFP Technologies (UFPT) - Fundamental Data Overview as of 25 May 2026
Market Cap USD = 1.77b (1.77b USD * 1.0 USD.USD)
P/E Trailing = 26.1083
P/E Forward = 21.8341
P/S = 2.9096
P/B = 4.0365
P/EG = 3.8011
Revenue TTM = 608.9m USD
EBIT TTM = 92.6m USD
EBITDA TTM = 116.3m USD
Long Term Debt = 125.1m USD (from longTermDebt, last quarter)
Short Term Debt = 17.5m USD (from shortTermDebt, last quarter)
Debt = 174.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 18.5m
Net Debt = 154.5m USD (calculated: Debt 174.5m - CCE 20.0m)
Enterprise Value = 1.93b USD (1.77b + Debt 174.5m - CCE 20.0m)
Interest Coverage Ratio = 10.60 (Ebit TTM 92.6m / Interest Expense TTM 8.73m)
EV/FCF = 27.74x (Enterprise Value 1.93b / FCF TTM 69.4m)
FCF Yield = 3.61% (FCF TTM 69.4m / Enterprise Value 1.93b)
FCF Margin = 11.41% (FCF TTM 69.4m / Revenue TTM 608.9m)
Net Margin = 11.27% (Net Income TTM 68.6m / Revenue TTM 608.9m)
Gross Margin = 28.35% ((Revenue TTM 608.9m - Cost of Revenue TTM 436.2m) / Revenue TTM)
Gross Margin QoQ = 28.77% (prev 28.18%)
Tobins Q-Ratio = 2.85 (Enterprise Value 1.93b / Total Assets 674.7m)
Interest Expense / Debt = 5.00% (Interest Expense 8.73m / Debt 174.5m)
Taxrate = 19.03% (4.11m / 21.6m)
NOPAT = 74.9m (EBIT 92.6m * (1 - 19.03%))
Current Ratio = 2.91 (Total Current Assets 224.1m / Total Current Liabilities 77.0m)
Debt / Equity = 0.40 (Debt 174.5m / totalStockholderEquity, last quarter 438.9m)
Debt / EBITDA = 1.33 (Net Debt 154.5m / EBITDA 116.3m)
Debt / FCF = 2.23 (Net Debt 154.5m / FCF TTM 69.4m)
Total Stockholder Equity = 413.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.42% (Net Income 68.6m / Total Assets 674.7m)
RoE = 16.61% (Net Income TTM 68.6m / Total Stockholder Equity 413.0m)
RoCE = 17.20% (EBIT 92.6m / Capital Employed (Equity 413.0m + L.T.Debt 125.1m))
RoIC = 12.59% (NOPAT 74.9m / Invested Capital 595.2m)
WACC = 10.26% (E(1.77b)/V(1.95b) * Re(10.87%) + D(174.5m)/V(1.95b) * Rd(5.00%) * (1-Tc(0.19)))
Discount Rate = 10.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 77.78 | Cagr: 0.50%
[DCF] Terminal Value 72.05% ; FCFF base≈65.3m ; Y1≈74.8m ; Y5≈110.1m
[DCF] Fair Price = 140.2 (EV 1.24b - Net Debt 154.5m = Equity 1.08b / Shares 7.74m; r=10.26% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 94.05 | EPS CAGR: 23.42% | SUE: 0.06 | # QB: 0
Revenue Correlation: 97.18 | Revenue CAGR: 22.47% | SUE: -0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=2.56 | Chg30d=+1.89% | Revisions=+25% | Analysts=4
EPS next Quarter (2026-09-30): EPS=2.74 | Chg30d=+1.01% | Revisions=+25% | Analysts=4
EPS current Year (2026-12-31): EPS=10.38 | Chg30d=+2.52% | Revisions=+43% | GrowthEPS=+6.4% | GrowthRev=+6.2%
EPS next Year (2027-12-31): EPS=11.69 | Chg30d=+2.05% | Revisions=+43% | GrowthEPS=+12.5% | GrowthRev=+6.1%
[Analyst] Revisions Ratio: +43%